Vaccine Packaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The vaccine packaging market size was valued at USD 4.61 billion in 2025 and estimated to grow from USD 4.89 billion in 2026 to reach USD 6.59 billion by 2031, at a CAGR of 6.12% during the forecast period (2026-2031). This report is Segmented by Packaging Type (Primary Packaging and Secondary Packaging), Material (Glass, Cyclic Olefin Polymer/Copolymer, and More), Dosage Capacity (Single-Dose, 2-5 Dose, and More), End User (Public Immunization Programs, Private Hospitals and Clinics, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Global Vaccine Packaging Market Trends and Insights

Intensified Immunization Campaigns and Booster Drives

National vaccination programs are scaling rapidly to close immunity gaps, illustrated by WHO’s call to reach 14.5 million previously unvaccinated children worldwide. Advisory bodies such as the CDC recommend thimerosal-free single-dose presentations for children and pregnant women, pushing demand for specialized containers. India’s Mission Indradhanush cut zero-dose prevalence to 0.06% in 2024, requiring enormous packaging throughput for 5.46 crore administered doses. UNICEF’s emergency mpox vaccine tender covering up to 12 million doses underscores the need for flexible vial formats that can ship quickly to crisis regions. Veterinary immunization is joining mainstream schedules as Elanco’s H5N1 cattle vaccine gains routine status, broadening packaging demand beyond human health.

Rising Prevalence of Emerging Infectious Diseases

Frequent pathogen evolution drives continuous package-ready reformulations. EMA’s recommendation to tailor COVID-19 vaccines to the LP.8.1 variant requires containers certified for accelerated stability studies. WHO-prequalified nOPV2 has already crossed 1 billion administered doses, highlighting enormous packaging volumes borne by a single manufacturer pipeline. During New York City’s 2023-2024 RSV season, 45% of nirsevimab doses were given in week 1 of life, affirming the requirement for neonatal-friendly, low-dead-space syringes. Resurgent measles and cholera outbreaks create unpredictable spikes that stretch fill-finish capacity. Merck Animal Health’s USD 895 million production expansion signals how zoonotic threats are also steering capital toward versatile packaging lines.

High Capex for Glass Tubing and Fill-Finish Lines

Modern vial plants produce tens of millions of containers daily, demanding automated inspection and strict quality control. Schott runs over 3,000 inspection stations across sites to achieve this scale. Thermo Fisher earmarked USD 1.5 billion of a larger USD 2 billion program solely for new life-science capital assets in the United States, highlighting the monetary hurdle to stay competitive. Secondary packaging is not exempt: Nosco’s new press boosts carton output by 125 million units yet required sizable upfront spend. Schott’s Perfexion inspection for tubing uses lasers and high-speed cameras, adding both cost and technical complexity. The capital intensity favors scale players and can slow adoption of niche materials or specialized vial designs.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Cold-Chain Capacity in Emerging Markets
• Shift Toward Single-Dose RTU Formats (Prefillable Syringes)
• Volatile Borosilicate Glass and Aluminosilicate Supply Chain

Segment Analysis

The vaccine packaging market size for primary containers remains anchored in glass vials, which secured 64.78% share in 2025, yet prefillable polymer syringes are outperforming at a 9.65% CAGR. Glass endures because of its chemical inertness and regulatory familiarity, particularly for lyophilized antigens. Meanwhile, demand for RTU convenience fuels syringe line investments that cut on-site washing, depyrogenation, and sterilization. Prefillable glass syringes act as a hybrid bridge, merging established glass chemistry with RTU workflow benefits. Vial closures and stoppers are evolving in parallel; metal-free PLASCAP® RUV seals eliminate secondary sterilization steps while meeting Annex 1 upgrades. On the secondary side, smart cartons and RFID-enabled labels transform boxes from passive protectors into real-time data hubs, aiding clinical trials, recalls, and patient engagement. Aluminium seals persist due to tamper evidence and recyclability, while emerging digital display labels remove manual relabeling and ensure protocol compliance.

Secondary packaging innovation supports broader supply-chain transparency. Schreiner MediPharm’s connected syringe boxes enable investigators to reconcile returned doses automatically, lowering error rates. NFC-embedded labels allow clinicians to tap a smartphone for real-time temperature logs, enhancing pharmacovigilance. Complementary advances in shipper insulation and GPS tracking minimize excursions and reduce spoilage insurance costs. Together, these developments reinforce the competitive edge of RTU formats, even as bulk glass vials remain fundamental during mass-vaccination surges.

Glass controlled 67.72% of revenue in 2025, yet COP/COC containers are expanding at an 8.86% CAGR as barrier performance improves. Delamination-resistant formulations such as EVERIC® pure address protein adsorption concerns, helping glass retain a dominant role for sensitive biologics. Nonetheless, polymer vials offer break resistance, weight savings, and lower extractables - appealing for field campaigns in remote areas. Polypropylene supplies lower-cost veterinary programs where temperature demands are less severe. Elastomer closure science is advancing in tandem, targeting reduced extractables and compatibility with ultra-low temperatures.

COP/COC can endure -80 °C storage while maintaining container-closure integrity, making them attractive for next-generation mRNA vaccines. Their glass-like transparency reassures clinicians during dose inspection, while reduced siliconization simplifies downstream analytical testing. Aluminum remains indispensable for flip-off caps, with suppliers tweaking alloys and coatings to support recyclability without sacrificing torque performance. Paperboard is winning back share in secondary cartons because EU regulations curb single-use plastics, and biobased films are gaining acceptance as inner liners in cold-chain shippers. Material selection is thus a dynamic trade-off between regulatory familiarity, performance, and sustainability.

Complete Report Scope:

• By Packaging Type
  • Primary Packaging
    • Glass Vials
    • Polymer Vials (COP, COC, PP)
    • Prefillable Glass Syringes
    • Prefillable Polymer Syringes
    • Vial Closures and Stoppers
    • Aluminum Seals and Caps
  • Secondary Packaging (cartons, labels, shippers)
• By Material
  • Glass (Borosilicate, Aluminosilicate)
  • Cyclic Olefin Polymer / Copolymer
  • Polypropylene (PP)
  • Elastomers (bromobutyl, chlorobutyl)
  • Aluminum
  • Paper and Paperboard
• By Dosage Capacity
  • Single-Dose Containers
  • 2-5 Dose Vials
  • 6-10 Dose Vials
  • More than 10 Dose Vials
• By End User
  • Public Immunization Programs
  • Private Hospitals and Clinics
  • Contract Manufacturing / CDMOs
  • Veterinary Vaccine Producers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia and New Zealand
    • ASEAN
    • Rest of Asia-Pacific
  • Middle East and Africa
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Turkey
    • Africa
      • South Africa
      • Nigeria
      • Egypt
      • Rest of Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

Europe led with 37.42% of 2025 revenue, underpinned by mature pharmaceutical manufacturing clusters, strict regulatory oversight, and entrenched cold-chain logistics. Germany illustrates rising downstream demand: pneumococcal vaccinations climbed 23% between 2018 and 2024, while meningococcal B uptake jumped 52% following new STIKO guidelines. EMA’s proactive variant-specific vaccine guidance compels local packaging lines to remain configurable for quick formulation changes. Sanofi’s 2025 European Immunization Week pointed to just 38% flu coverage in adults over 60, signaling room for packaging-driven access initiatives.

Asia-Pacific is the fastest growing at 9.18% CAGR as governments invest heavily in production autonomy and distribution infrastructure. India’s reduction of zero-dose children demonstrates effective program execution, demanding large yet agile packaging volumes suited to varied climates. China’s expanding biologics sector and Japan’s precision engineering elevate regional standards, while ASEAN nations roll out new domestic plants, often through joint ventures with European glass makers. Improved port and road logistics help maintain cold-chain integrity, further lifting market potential.

North America maintains robust demand through innovation leadership and stringent FDA oversight. Thermo Fisher’s multibillion-dollar investment strengthens domestic supply resilience, while CDC recommendations continue shaping container specifications, particularly around preservative-free pediatric doses. The Middle East & Africa and South America collectively form an emerging opportunity as they upgrade immunization schedules and deploy new regional manufacturing hubs, often supported by multilateral funding. Packaging suppliers focusing on cost-efficient glass/polymer hybrids and rugged shippers are well-positioned to capture incremental share.

List of Companies Covered in this Report:

• Gerresheimer AG
• Schott AG
• Stevanato Group
• Becton, Dickinson & Co.
• Corning Inc.
• West Pharmaceutical Services
• SGD Pharma
• Nipro Corporation
• SiO2 Materials Science
• DWK Life Sciences
• Thermo Fisher Scientific
• Aptar Group
• Owens-Illinois (O-I)
• WestRock
• Catalent Inc.
• Ardagh Group
• Piramal Glass
• Shandong Pharmaceutical Glass
• Copan Italia
• SiCortex BioSystems

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support